NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024
Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024
Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …

Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam

January 11, 2024
Sales and Marketing Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration

Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in …

Isomorphic Labs to collaborate with Eli Lilly

January 11, 2024
Research and Development AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery

Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

January 10, 2024
Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

Fate Therapeutics initiates phase 1 trial for solid tumour treatment

January 9, 2024
Research and Development Fate Therapeutics, Oncology, solid tumours

Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …

GSK to acquire Aiolos Bio for $1bn

January 9, 2024
Business Services Aiolos Bio, GSK, Pharmacy, acquisition

GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …

Consilient Health to launch Cytisine smoking cessation treatment in UK

January 8, 2024
Sales and Marketing Cytisine, Smoking Cessation, consilient health, smoking cessation

Consilient Health has announced that it plans to launch Cytisine 1.5mg tablets in the UK on 22 January 2024. The …

Calypso Biotech to be acquired by Novartis for $250m

January 8, 2024
Business Services Calypso Biotech, Immunology, Novartis, acquisition

Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …

national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024
Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement

January 5, 2024
Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial

Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …

Renovos Biologics gains FDA Breakthrough Device Designation for Renovite

January 4, 2024
Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation

Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …

Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery

January 4, 2024
Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology

Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …

C4X receives $11m milestone payment from AstraZeneca

January 3, 2024
Sales and Marketing AstraZeneca, C4X, C4X Discovery, Chronic Diseases

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered …

minku-kang-acnintiifd8-unsplash_1

Proteome Sciences completes new facility in San Diego, US

January 3, 2024
Manufacturing and Production Pharmacy, Proteome Sciences, facility, san diego

Proteome Sciences has announced that it has completed the installation and set up of equipment in its new laboratory facility …

AstraZeneca and Sanofi’s Beyfortus approved in China

January 2, 2024
Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

January 2, 2024
Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …

Calliditas Therapeutics gains FDA approval of Tarpeyo

December 22, 2023
Medical Communications Calliditas, FDA, Nephrology, kidneys

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …

FDA approves AstraZeneca and Ionis’s Wainua

December 22, 2023
Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua

AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …

Latest content